Zirconium (89Zr) crefmirlimab berdoxam

HOUSTON, Aug. 10, 2022 /PRNewswire/ -- UC Davis, a leading university in molecular imaging that collaborated with United Imaging to develop the world's first total-body PET/CT scanner, 'uEXPLORER®,' recently presented their research on COVID-19 at the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. Guided by the uEXPLORER scanner along with a new labeled radiotracer with high affinity to T cells (89Zr-Crefmirlimab-Berdoxam), UC Davis Project Scientist and lead author Dr. Negar Omidvari unveiled the first high-resolution PET image of total-body CD8+ T-cell distribution after COVID-19 infection. The image could shed light on the pathological mechanism and immune response to COVID-19 infection. Continue Reading The first reported image of CD8+ T cell distribution in a recovered COVID-19 patient (F, 29 y/o, BMI 29), imaged 7 weeks post symptom onset on the uEXPLORER total-body PET/CT scanner, using a ~0.5 mCi injected dose of 89Zr-Df-Crefmirlimab-Berdoxam. Lymphoid organs containing CD8+ T cells (such as spleen, bone marrow, lymph nodes, and tonsils) showed the largest uptake, reflected by the darker black parts of the image. Image courtesy of Dr. Negar Omidvari at UC Davis. Dr. Simon R. Cherry (left) and Dr. Ramsey D. Badawi (right) standing in front of the uEXPLORER scanner. Cytotoxic T cells are key players in the cell-mediated immune response against viral infections. However, 95% of T cells are in tissues rather than in the blood circulation and are therefore difficult to assess non-invasively. High sensitivity PET imaging using a specific T cell radiotracer offers a new methodology to track tissue concentrations of T cells without invasive sampling. The radiotracer used, 89Zr-Crefmirlimab-Berdoxam, is an investigational tracer provided for the study by ImaginAb who is currently in Phase IIb testing to determine predictive performance. In the reported study, patients recovering from COVID-19 infection received a low injection dose (~0.5 mCi) of 89Zr-labeled radiotracer that targeted CD8+ T cells and underwent a uEXPLORER PET/CT scan at different time points. A control group was also studied. The total-body PET images revealed subtle differences between five recovering COVID-19 patients and three healthy volunteers. The exceptional image quality obtained using the uEXPLORER scanner confirmed CD8+ T cell deposition in the spleen, liver, bone marrow, lymph nodes, and tonsils, as well as differences in the clearance rate of the radiotracer from the blood. Imaging was accomplished with minimal radiation dose to the patients. This research paves the way for further exploration of the assessment of immune response to infectious diseases and cancer, the assessment of response to vaccines in human subjects, and the fundamental mechanisms of the immune system in general. This disruptive technology co-developed by UC Davis and United Imaging was selected as one of the "2018 Breakthroughs of the Year" by Physics World. It pushes the boundaries of traditional PET scanners, with an effective sensitivity that is up to 68-fold greater than current commercial PET scanners. Combined with a 194 cm axial PET field of view, the uEXPLORER scanner can capture dynamic changes to radiotracer distribution across the entire human body with high temporal resolution, which is an essential attribute for this type of research. Simon R. Cherry, Ph.D., Distinguished Professor of Biomedical Engineering and Radiology at UC Davis, was recently awarded the Benedict Cassen Prize at the 2022 SNMMI annual meeting for his pioneering work and immense contributions to nuclear medicine instrumentation and molecular imaging. He commented: "We have now contributed to several different disease areas based on the high sensitivity and total-body coverage of the uEXPLORER scanner. This research is another demonstration of how groundbreaking imaging technology, combined with highly specific radiotracers, can open new opportunities in studying the complex interactions within the whole body, both in health and in response to disease. We hope this research will contribute to a better understanding of the immunological response to COVID-19, and serve as an example for how the immune system can be interrogated at a systems level with total-body PET." SOURCE United Imaging Healthcare Co., Ltd.

LOS ANGELES and SAN DIEGO, Jan. 28, 2021 /PRNewswire/ -- ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement. Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN's development teams. ImaginAb will receive license fees and other contingent payments. No other terms were disclosed. ImaginAb's PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients, enabling confirmation of drug mechanism and indication of the cancer immunotherapies' efficacy. Previous clinical studies have shown the clinical relevance of ImaginAb's 89Zr CD8 Immuno-PET imaging agent, and the use of these imaging data sets potentially contributes to improving the standard of care in immune-oncology therapies. The company's goal is to enable widespread use and adoption of 89Zr CD8 Immuno-PET technology. ImaginAb's CEO, Ian Wilson, commented: "We are delighted and very excited to work with NEUVOGEN and support the clinical development of their novel therapeutic cancer vaccine candidates. CD8 T cells play a pivotal role in cancer immunotherapy and our clinical studies have shown our 89Zr CD8 Immuno-PET imaging agent tracks and quantifies CD8 T cells in patients. We believe combining CD8 imaging with NEUVOGEN's whole cell cancer vaccines will enable more robust clinical data sets and accelerate the development of novel treatment protocols for solid tumors." NEUVOGEN's next-generation whole cell cancer vaccines are designed to simultaneously prime the broadest array of tumor targets, impacting multiple biologic pathways with the goal of directing an immune response against overlapping targets on every cell within a tumor. ImaginAb's T Cell specific PET imaging technology allows the NEUVOGEN team to visualize Tumor Infiltrating Lymphocytes, and monitor the dynamics of CD8 T cells in response to its novel cancer vaccine therapies, without the need for multiple tumor biopsies. "This agreement provides NEUVOGEN access to highly specific and precise imaging of the presence of CD8 T Cells in solid tumors over time." said Todd Binder, Chief Executive Officer, NEUVOGEN. "ImaginAb's 89Zr CD8 Immuno-PET imaging agent will help our development teams determine changes in CD8 T cell tumor infiltrates induced by NEUVOGEN's therapies, an important indicator of a patient's successful immune response to our vaccine therapy." About ImaginAb ImaginAb Inc. is a market leading biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets including the 89Zr CD8 ImmunoPET targeting CD8 T cells. ImaginAb's products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine ventures Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb's pipeline and technology, visit . About CD8 Immuno-PET The 89Zr CD8 Immuno-PET agent ([89Zr]-Df-IAB22M2C) is a Zirconium-89 labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes. About NEUVOGEN NEUVOGEN, Inc. is an immune-oncology company focused on whole cell cancer vaccine therapies. NEUVOGEN believes its cancer vaccines have the broadest combination of tumor associated antigens and tumor specific antigens ever delivered in a cancer vaccine and as a result can directly target a greater percentage of cancer cells in a solid tumor than any previous cancer vaccine. Based in San Diego, California, NEUVOGEN's goal is to develop therapeutic cancer vaccines that activate the body's immune system to eradicate solid tumors and meaningfully extend the lives of patients while limiting side effects. To learn more, visit . For further information please contact: ImaginAb Ian Wilson info@imaginab.com NEUVOGEN Cyrus Arman partnering@neuvogen.com Christine Dusek media@neuvogen.com View original content to download multimedia: SOURCE ImaginAb, Inc.